

## Indonesia Support for Inactivated Polio Vaccine (IPV)

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Indonesia																				
<b>2. Grant number:</b> 1618-IDN-25b-X / 1618-IDN-25c-X / 15-IDN-08h-Y																				
<b>3. Date of Decision Letter:</b> 28 April 2016																				
<b>4. Date of the Partnership Framework Agreement:</b> 30 December 2014																				
<b>5. Programme title:</b> NVS, IPV routine																				
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)																				
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID, 10 dose(s) per vial, LIQUID																				
<b>8. Programme duration<sup>2</sup>:</b> 2016 - 2018																				
<p><b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)</p> <p><i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i></p> <p>IPV 5-dose(s) presentation (Grant number 1618-IDN-25b-X)</p> <table border="1" style="width: 100%; border-collapse: collapse; margin: 5px 0;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 20%;">2016</th> <th style="width: 20%;">2017</th> <th style="width: 20%;">2018</th> <th style="width: 20%;">Total<sup>3</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td style="text-align: right;">US\$1,746,500</td> <td style="text-align: right;">US\$8,326,500</td> <td style="text-align: right;">US\$8,141,000</td> <td style="text-align: right;">US\$18,214,000</td> </tr> </tbody> </table> <p>IPV-10 dose(s) presentation (Grant number 1618-IDN-25c-X)</p> <table border="1" style="width: 100%; border-collapse: collapse; margin: 5px 0;"> <thead> <tr> <th style="width: 20%;"></th> <th style="width: 20%;">2016</th> <th style="width: 20%;">2017</th> <th style="width: 20%;">2018</th> <th style="width: 20%;">Total<sup>4</sup></th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td style="text-align: right;">US\$1,757,000</td> <td style="text-align: center;">-</td> <td style="text-align: center;">-</td> <td style="text-align: right;">US\$1,757,000</td> </tr> </tbody> </table>		2016	2017	2018	Total <sup>3</sup>	Programme Budget (US\$)	US\$1,746,500	US\$8,326,500	US\$8,141,000	US\$18,214,000		2016	2017	2018	Total <sup>4</sup>	Programme Budget (US\$)	US\$1,757,000	-	-	US\$1,757,000
	2016	2017	2018	Total <sup>3</sup>																
Programme Budget (US\$)	US\$1,746,500	US\$8,326,500	US\$8,141,000	US\$18,214,000																
	2016	2017	2018	Total <sup>4</sup>																
Programme Budget (US\$)	US\$1,757,000	-	-	US\$1,757,000																
<b>10. Vaccine introduction grant (in US\$):</b> US\$ 3,688,500. Disbursed to Indonesia on 28 November 2014.																				

<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

<sup>4</sup> This is the total amount endorsed by Gavi for 2015 to 2018.

**11. Indicative Annual Amounts:** (subject to the terms of the Partnership Framework Agreement, if applicable)<sup>5</sup>

IPV 5-dose(s) presentation (Grant number 1618-IDN-25b-X)  
 IPV 10-dose(s) presentation (Grant number 1618-IDN-25c-X)

Type of supplies to be purchased with Gavi funds in each year	2016
Number of IPV vaccines doses	878,000
Number of AD syringes	847,900
Number of re-constitution syringes	
Number of safety boxes	9,350
Annual Amounts (US\$)	US\$1,746,500
Type of supplies to be purchased with Gavi funds in each year	2016
Number of IPV vaccines doses	1,860,000
Number of AD syringes	1,718,700
Number of re-constitution syringes	
Number of safety boxes	18,925
Annual Amounts (US\$)	US\$1,757,000

1. Procurement agency: Not applicable.

2. Self-procurement: Self-procurement applies to Gavi funds.

3. Co-financing obligations: Not applicable  
 Gavi's usual co-financing requirements do not apply to IPV. However, Indonesia is encouraged to contribute to vaccine and/or supply costs for IPV.

4. Operational support for campaigns: Not applicable

<sup>5</sup> This is the amount that Gavi has approved.

<b>5. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>6. Financial clarifications:</b> Not applicable.	
<i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.</i>	
<b>7. Other conditions:</b>	
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual number of doses shipped may differ from the amounts specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Indonesia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Indonesia.</p>	

Signed by,  
**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
28 April 2016